Skeletal muscle remodeling

Current Opinion in Rheumatology

Volumn 19, Issue 6, 2007, Pages 542-549

  Potthoff, Matthew J ^a   Olson, Eric N ^a   Bassel Duby, Rhonda ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Atrophy; Hypertrophy; Myofiber; Myopathy; Signal transduction pathway

Indexed keywords

CALCINEURIN; HISTONE DEACETYLASE; MICRORNA; MYOCYTE ENHANCER FACTOR 2;

CLINICAL MEDICINE; DEPLETION; GENE CONTROL; GENE EXPRESSION PROFILING; GENE TARGETING; GENETIC ENGINEERING; HUMAN; MICROARRAY ANALYSIS; MUSCLE FATIGUE; MUSCLE FIBRIL; MUSCLE HYPERTROPHY; MUSCLE INJURY; MUSCLE MASS; MYOPATHY; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TRANSGENIC MOUSE;

ANIMALS; GENE EXPRESSION; HUMANS; MUSCLE, SKELETAL; SIGNAL TRANSDUCTION;

EID: 34948886117     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3282efb761     Document Type: Review

References (56)

1. Schiaffino S, Reggiani C. Molecular diversity of myofibrillar proteins: gene regulation and functional significance. Physiol Rev 1996; 76:371-423.
2. Bassel-Duby R, Olson EN. Signaling pathways in skeletal muscle remodeling. Annu Rev Biochem 2006; 75:19-37. This review comprehensively describes the signaling mechanisms that modify myofiber function with emphasis on clinical significance and therapeutic approaches to ameliorate muscle diseases.
3. Garry DJ, Bassel-Duby RS, Richardson JA, et al. Postnatal development and plasticity of specialized muscle fiber characteristics in the hindlimb. Dev Genet 1996; 19:146-156.
4. Baldwin KM, Haddad F. Effects of different activity and inactivity paradigms on myosin heavy chain gene expression in striated muscle. J Appl Physiol 2001; 90:345-357.
5. Sieck GC, Regnier M. Invited review: plasticity and energetic demands of contraction in skeletal and cardiac muscle. J Appl Physiol 2001; 90:1158-1164.
6. Talmadge RJ. Myosin heavy chain isoform expression following reduced neuromuscular activity: potential regulatory mechanisms. Muscle Nerve 2000; 23:661-679.
7. Olson EN, Williams RS. Calcineurin signaling and muscle remodeling. Cell 2000; 101:689-692.
8. Oh M, Rybkin II, Copeland V, et al. Calcineurin is necessary for the maintenance but not embryonic development of slow muscle fibers. Mol Cell Biol 2005; 25:6629-6638.
9. Stupka N, Schertzer JD, Bassel-Duby R, Olson EN, Lynch GS. Calcineurin-A{alpha} activation enhances the structure and function of regenerating muscles after myotoxic injury. Am J Physiol Regul Integr Comp Physiol. 2007; 2 May [Epub ahead of print].
10. Potthoff J, Olson EN. MEF2: a central regulator of diverse developmental programs. Development (in press).
11. McKinsey TA, Olson EN. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J Clin Invest 2005; 115:538-546.
12. Naya FJ, Wu C, Richardson JA, et al. Transcriptional activity of MEF2 during mouse embryogenesis monitored with a MEF2-dependent transgene. Development 1999; 126:2045-2052.
13. Wu H, Rothermel B, Kanatous S, et al. Activation of MEF2 by muscle activity is mediated through a calcineurin-dependent pathway. EMBO J 2001; 20:6414-6423.
14. Potthoff MJ, Wu H, Arnold MA, et al. Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofibers. J Clin Invest 2007; 117:2459-2467.
15. Berdeaux R, Goebel N, Banaszynski L, et al. SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes. Nat Med 2007; 13: 597-603.
16. Wu H, Kanatous SB, Thurmond FA, et al. Regulation of mitochondrial biogenesis in skeletal muscle by CaMK. Science 2002; 296:349-352.
17. van der Linden AM, Nolan KM, Sengupta P. KIN-29 SIK regulates chemoreceptor gene expression via an MEF2 transcription factor and a class II HDAC. EMBO J 2007; 26:358-370.
18. Chen AE, Ginty DD, Fan CM. Protein kinase A signalling via CREB controls myogenesis induced by Wnt proteins. Nature 2005; 433:317-322.
19. Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev 2006; 27:728-735. This review highlights the transcriptional coactivator PGC-1 family as a strong activator of mitochondrial function and a dominant regulator of oxidative metabolism in a variety of tissues. Studies have elucidated the function of the PGC-1 coactivators in different tissues and have implicated PGC-1 dysregulation in diseases such as diabetes, obesity, cardiomyopathy, or neurodegeneration.
20. Lin J, Wu H, Tarr PT, et al. Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 2002; 418:797-801.
21. Arany Z, He H, Lin J, et al. Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab 2005; 1:259-271.
22. Czubryt MP, McAnally J, Fishman GI, Olson EN. Regulation of peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1 alpha) and mitochondrial function by MEF2 and HDAC5. Proc Natl Acad Sci USA 2003; 100:1711-1716.
23. Handschin C, Kobayashi YM, Chin S, et al. PGC-1alpha regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy. Genes Dev 2007; 21:770-783.
24. Arany Z, Lebrasseur N, Morris C, et al. The transcriptional coactivator PGC-1beta drives the formation of oxidative type IIX fibers in skeletal muscle. Cell Metab 2007; 5:35-46.
25. Barish GD, Narkar VA, Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006; 116:590-597.
26. Schuler M, Ali F, Chambon C, et al. PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes. Cell Metab 2006; 4:407-414.
27. Lee CH, Olson P, Hevener A, et al. PPARdelta regulates glucose metabolism and insulin sensitivity. Proc Natl Acad Sci USA 2006; 103:3444-3449.
28. Wang YX, Lee CH, Tiep S, et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003; 113:159-170.
29. Grifone R, Laclef C, Spitz F, et al. Six1 and Eya1 expression can reprogram adult muscle from the slow-twitch phenotype into the fast-twitch phenotype. Mol Cell Biol 2004; 24:6253-6267.
30. Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 2005; 37:1974-1984.
31. Leger B, Cartoni R, Praz M, et al. Akt signalling through GSK-3beta, mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophy. J Physiol 2006; 576:923-933.
32. Bodine SC. mTOR signaling and the molecular adaptation to resistance exercise. Med Sci Sports Exerc 2006; 38:1950-1957.
33. Mourkioti F, Kratsios P, Luedde T, et al. Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. J Clin Invest 2006; 116:2945-2954.
34. Reecy JM, Spurlock DM, Stahl CH. Gene expression profiling: insights into skeletal muscle growth and development. J Anim Sci 2006; 84 Suppl:E150-E154. This review discusses how microarray technology has been applied to study global gene expression changes in skeletal muscle.
35. Hittel DS, Hathout Y, Hoffman EP. Proteomics and systems biology in exercise and sport sciences research. Exerc Sport Sci Rev 2007; 35:5-11. This review describes recent advances in mass spectrometry-based proteomics and their application toward interpreting the physiological adaptations of skeletal muscle with exercise and obesity.
36. Wu H, Gallardo T, Olson EN, et al. Transcriptional analysis of mouse skeletal myofiber diversity and adaptation to endurance exercise. J Muscle Res Cell Motil 2003; 24:587-592.
37. Mahoney DJ, Parise G, Melov S, et al. Analysis of global mRNA expression in human skeletal muscle during recovery from endurance exercise. FASEB J 2005; 19:1498-1500.
38. Urso ML, Scrimgeour AG, Chen YW, et al. Analysis of human skeletal muscle after 48 h immobilization reveals alterations in mRNA and protein for extracellular matrix components. J Appl Physiol 2006; 101:1136-1148.
39. Morikawa S, Murakami T, Yamazaki H, et al. Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins. J Atheroscler Thromb 2005; 12:121-131.
40. Viguerie N, Clement K, Barbe P, et al. In vivo epinephrine-mediated regulation of gene expression in human skeletal muscle. J Clin Endocrinol Metab 2004; 89:2000-2014.
41. Raju R, Dalakas MC. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 2005; 128:1887-1896.
42. Zhou X, Dimachkie MM, Xiong M, et al. cDNA microarrays reveal distinct gene expression clusters in idiopathic inflammatory myopathies. Med Sci Monit 2004; 10:BR191-BR197.
43. Gelfi C, Vigano A, De Palma S, et al. 2-D protein maps of rat gastrocnemius and soleus muscles: a tool for muscle plasticity assessment. Proteomics 2006; 6:321-340.
44. Le Bihan MC, Hou Y, Harris N, et al. Proteomic analysis of fast and slow muscles from normal and kyphoscoliotic mice using protein arrays, 2-DE and MS. Proteomics 2006; 6:4646-4661.
45. Okumura N, Hashida-Okumura A, Kita K, et al. Proteomic analysis of slow- and fast-twitch skeletal muscles. Proteomics 2005; 5:2896-2906.
46. Doran P, Donoghue P, O'Connell K, et al. Proteomic profiling of pathological and aged skeletal muscle fibres by peptide mass fingerprinting. Int J Mol Med 2007; 19:547-564. This review discusses the recent progress in the biochemical analysis of skeletal muscle extracts and outlines the mass spectrometry-based proteomics approach for studying muscle tissues in normal and pathobiochemical processes.
47. Li J, Yin C, Okamoto H, et al. Proteomic analysis of inclusion body myositis. J Neuropathol Exp Neurol 2006; 65:826-833.
48. Krutzfeldt J, Stoffel M. MicroRNAs: a new class of regulatory genes affecting metabolism. Cell Metab 2006; 4:9-12. This study describes the possibility that miRNAs may contribute to common metabolic diseases and points to novel therapeutic opportunities based on targeting of miRNAs.
49. Chen JF, Mandel EM, Thomson JM, et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006; 38:228-233. This study describes the role and the targets of miR-1 and miR-133 in skeletal muscle proliferation and differentiation. These findings suggest a molecular mechanism in which miRNAs participate in transcriptional circuits that control skeletal muscle gene expression and embryonic development.
50. McCarthy JJ, Esser KA. MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy. J Appl Physiol 2007; 102:306-313. This study determines the expression level of the muscle-specific miRNAs in the skeletal muscle. Results from this study show alterations in expression of muscle-specific miRNAs in adult skeletal muscle and suggest miRNAs may have a role in the adaptation to functional overload.
51. Kim HK, Lee YS, Sivaprasad U, et al. Muscle-specific microRNA miR-206 promotes muscle differentiation. J Cell Biol 2006; 174:677-687.
52. McCarthy JJ, Esser KA, Andrade FH. MicroRNA-206 is over-expressed in the diaphragm but not the hindlimb muscle of mdx mouse. Am J Physiol Cell Physiol 2007; 293:C451-C457.
53. Clop A, Marcq F, Takeda H, et al. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat Genet 2006; 38:813-818.
54. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438:685-689.
55. Fielitz J, Kim M, Shelton JM, et al. Myosin accumulation and striated muscle myopathy resulting from the loss of Muscle RING Finger 1 and 3. J Clin Invest 2007 in press.
56. van Rooij E, Sutherland LB, Qi X, et al. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007; 316: 575-579.